Investor FAQs
|
|
- Corporate information |
|
- Equity shares information |
|
- Investor calendar |
- Investor contact information
|
Corporate Information
|
| 1. What is Biocon's area of operations? |
Biocon is an integrated biotechnology enterprise focused on the development of biopharmaceuticals. The Biocon group of companies consists of Biocon - the flagship, holding company and its subsidiaries, Syngene, Clinigene and a joint venture company, Biocon Biopharmaceuticals. Principal areas of operations include:
|
|
Biopharmaceuticals
|
Biocon’s pharmaceuticals business comprises the manufacture and development of active pharmaceuticals ingredients (APIs) and bulk drugs, with a focus on products involving fermentation and/or synthetic conversion. Our biopharmaceuticals business, however, primarily seeks to leverage the expiry of product patents for key Statins - Simvastatin, Lovastatin, Atorvastatin and Pravastatin through research capabilities and fermentation and synthetic chemistry skills that have been developed over the years at Biocon.
|
| Custom & Clinical Research Services |
Biocon provides contract research services to overseas and domestic customers in the following areas:
|
|
- Molecular Biology |
|
- Synthetic Chemistry |
|
- Bioinformatics |
- Clinical research on well-defined and
characterised patients suffering from chronic diseases such as diabetes,
osteoporosis, asthma, etc.
|
| 2. What is the address of Biocon’s registered office? |
|
Biocon has its corporate and registered office at Bangalore.
|
BIOCON LIMITED
20th KM, Hosur Road
Electronic City PO
Bangalore - 560 100
Ph +91 80 2808 2808
Fax +91 80 2852 3423
|
|
3. Where and in which year was Biocon incorporated?
|
Biocon was incorporated on November 11, 1978 in Bangalore, India.
|
|
4. What is the total employee strength at Biocon Group?
|
Team Biocon comprises of 3,454 employees (as on March 31st, 2009) in various field, with a strong scientist portfolio.
|
| 5. What is Biocon’s revenue and profits for the recently concluded quarter and for the last 12 months? |
| |
Q4 FY09 |
FY 09 |
| Revenues |
486 |
1673 |
Profit After Tax (After Exceptional item) |
25 |
93 |
|
6. Where can I obtain information on Biocon’s financial results? |
To obtain the financial results of the company, please refer to our website under the Investor Relations. Alternatively, the same is also available at the website of National Stock Exchange (NSE) and Mumbai Stock Exchange (BSE).
|
The results of the company are also published in Business Daily, Business Standard.
|
| 7. Who are the members on Biocon’s Board of Directors? |
|
Biocons' Board consists of:
|
|
Dr. Kiran Mazumdar-Shaw, Chairman and Managing Director
|
|
Mr. John Shaw
|
|
Dr. Neville Bain
|
|
Prof Charles L Cooney
|
|
Mr. Suresh Talwar
|
|
Prof Ravi Mazumdar
|
|
Dr. Bala Manian
|
Prof Catherine Rosenberg, Alternate Director
|
Equity Shares Information
|
|
1. When did Biocon have its Initial Public Offer (IPO) ?
|
In March 2004, Biocon went public with an IPO of 10,000,000 fresh equity shares of Rs. 5 each at a price of Rs. 315 per share.
|
|
2. On which stock exchanges are Biocon shares listed and what are the codes?
|
| Name of Exchange |
Code |
| National Stock Exchange, Mumbai (NSE) |
BIOCON |
| Mumbai Stock Exchange, (BSE) |
532523 |
|
3. Where can I obtain details on Biocon’s stockholders? |
Details of shareholding pattern of the company as at March 31, 2009 is available in the Annual Report, downloadable from our website. The same is also available on the NSE and BSE websites.
|
|
4. Does Biocon pay dividends?
|
The Company declared a dividend of 60% (i.e., Rs. 3/- per share) for the fiscal year 2009.
|
|
5. What is the percentage breakdown of shareholders?
|
|
The shareholding pattern of Biocon shares as at March 31, 2009 |
| Employees and ESOP Trust |
8% |
| Promoters |
61% |
| Public and Institutional & Others |
31% |
|
Investor Calendar
|
|
1. What is the date of release of financial results?
|
|
The tentative calendar for the financial results for the fiscal year 2010 is as follows: |
| Q1 FY 2010 |
July 23, 2009 |
| Q2 FY 2010 |
October 22, 2009 |
| Q3 FY 2010 |
January 21, 2010 |
| Q4 FY 2010 |
April 29, 2010 |
|
2. When is the next AGM? |
The Annual General Meeting (AGM) of the Company for the year 2008-09 is proposed to be held on July 23, 2009
|
|
3. Does the Company have any quiet periods?
|
|
Yes. Biocon follows quiet periods prior to its quarterly results ie. starting at the end of the last quarter and ending on the day of announcement of earnings. During this time, the Company or any of its officials will not discuss earnings expectations with any external parties. Based on tentative dates of earnings release in fiscal 2010, the tentative quiet periods would be as follows: |
| Quarter ending |
Earnings release date |
Quiet period |
| June 30, 2009 |
July 23, 2009 |
Jul 1, 2009 to Jul 23, 2009 |
| Sep 30, 2009 |
October 22, 2009 |
Oct 1, 2009 to Oct 22, 2009 |
| Dec 31, 2009 |
Jan 21, 2010 |
Jan 1, 2010 to Jan 21, 2010 |
| Mar 31, 2010 |
Apr 29, 2010 |
Apr 1, 2010 to Apr 29, 2010 |
|
Investor Contact Information
|
|
Investor Contact
|
|
- For queries relating to financial statement & investor matters |
Jill Deviprasad
Investor Relations
Biocon Corporate Headquarters
20th KM, Hosur Road,
Electronics City,
Bangalore,
Karnataka -
India
Pin
- 560 100 |
| Email: jill.deviprasad@biocon.com |
| Email: investor.relations@biocon.com |
| |
| - For compliance matters and for matters relating to shares/dividend: |
| Email: co.secretary@biocon.com |
| - Details of Registrar and Share Transfer Agents: |
| Email: mahender@karvy.com |
